Citation:Cruz-Gonzalez F,Cabrillo-Estevez L,Rivero-Gutierrez V,Sanchez-Jara A,Juan-Marcos LD,Gonzalez-Sarmiento R.Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population.Int J Ophthalmol 2016;9(9):1304-1309,doi:10.18240/ijo.2016.09.12
Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population
Received:September 17, 2015  Revised:December 04, 2015
Email this Article  Add to Favorites  Print
DOI:10.18240/ijo.2016.09.12
Key Words:age-related macular degeneration; polymorphisms; ARMS2; HTRA1; complement factor H; ranibizumab
Fund Project:Supported by a Grant from Gerencia Regional de Salud de Castillay Leon GRS 957/A/14.
                 
AuthorInstitution
Fernando Cruz-Gonzalez Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain
Lucia Cabrillo-Estevez Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain
Vanesa Rivero-Gutierrez Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain
Ana Sanchez-Jara Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain
Lourdes De Juan-Marcos Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain
Rogelio Gonzalez-Sarmiento Department of Ophthalmology, Hospital Universitario Salamanca, Salamanca 37007, Spain
Hits: 759
Download times: 143
Abstract:
      AIM: To determine whether gene polymorphisms of the major genetic risk loci for age-related macular degeneration (AMD): ARMS2 (rs10490923), the complement factor H (CFH) (rs1410996) and HTRA1 (rs11200638) influence the response to a treatment regimen with ranibizumab for exudative AMD.

    METHODS: This study included 100 patients (100 eyes) with exudative AMD. Patients underwent a treatment with ranibizumab injections monthly during three months. Reinjections were made when the best corrected visual acuity (BCVA) decrease five letters (ETDRS) or central subfield retinal thickness gained 100 μm in optical coherence tomography image. Genotypes (rs10490923, rs1410996 and rs11200638) were analyzed using TaqMan probes or polymerase chain reaction-restricted fragment length polymorphisms analysis.

    RESULTS: There were no statistically significant differences in allelic distribution of CFH (rs1410996), ARMS2 (rs10490923) and HTRA1 (rs11200638) polymorphisms regarding to response to ranibizumab treatment.

    CONCLUSION: Ranibizumab treatment response is not related to CFH (rs1410996), ARMS2 (rs10490923) and HTRA1 (rs11200638) poymorphisms.

PMC FullText Html:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028666/
附件
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment